A Dose Escalation Study of Gefapixant (AF-219/MK-7264) in Refractory Chronic Cough (MK-7264-010)
Status:
Completed
Trial end date:
2016-02-09
Target enrollment:
Participant gender:
Summary
A randomized, double-blind, placebo-controlled, crossover, dose escalation study to assess
the efficacy and tolerability of gefapixant (AF-219; MK-7264) in participants with refractory
chronic cough.